Skip to main content

Table 4 Effect of mTOR inhibitor therapy on IS and neurodevelopment

From: Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

Patient #

Age at start of mTOR inhibitor

AAO of IS

Previous treatment

Time to cessation of IS

Development prior to start of mTOR inhibition

Development during follow-up

1

19 months

7 months

VGB

16 months

Normal

DD (not specified)

2

14 months

5 months

VGB

3 months

DD (global)

DD (not specified)

3

15 months

6 months

VGB

NA

DD (motor)

Normal

7

5 months

NA

ACTH, VGB

1 month

Normal

DD (speech)

9

7 days

7 months

VGB

4 months

NA

DD (global)

11

7 days

1 month

VGB

NA

NA

DD (global)

12

1 day

5 months

VGB

1 month

NA

DD (global)

  1. AAO age at onset, IS infantile spasms